Thriving life science firm Sphere Fluidics expands Tech Corridor operations
A growing life science firm has moved into new office space in Cambridge.
Sphere Fluidics, which is commercialising single cell analysis systems underpinned by its patented picodroplet technology, has taken space at the McClintock Building at Granta Park.
The new facilities support the company’s accelerated expansion and accommodate its plans for further growth. Sphere Fluidics recently closed a $4.8m (£3.7m) funding round, enabling it to hire 10 new staff to expand commercial capabilities and facilitate service and support for its Cyto-Mine Single Cell Analysis System.
Cyto-Mine integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run.
Sphere Fluidics, developer of Cyto-Mine, right, has moved into new offices at Granta Park
The company’s sales, marketing, finance and operations teams will be based at Granta Park, which is home to over 2,500 people and multiple organisations, opening up the opportunity for further collaborations with potential partners, researchers and suppliers based on the campus.
Sphere’s new facilities will compliment its offices at Babraham Research Campus, and Monmouth Junction, New Jersey, USA.
Rob Treanor, director of operations for Sphere Fluidics, said: “Recent investment has enabled Sphere Fluidics to accelerate its plans to expand commercial and scientific activities and we are now raising further funding to invest in more new hires and increase our presence in not only the UK but also, the US. It is vital that we are positioned in locations with a flexible and innovative network and look forward to joining the collaborative culture at Granta Park to support these growth projections.”
